BofA upgrades DraftKings stock rating on prediction market outlook

BofA Securities upgraded DraftKings to Buy from Neutral, keeping its $27 price target unchanged; the stock had fallen 47% over the past year to $18.59, near its 52-week low of $18.52. BofA sees prediction markets as a potential win-win, with lower cannibalization risk and Street estimates bottoming. Other firms maintained Buy or Market Outperform ratings with targets of $30–$36, while StoneX cut its 2026 EBITDA estimate to $575 million because of higher expected investment in DraftKings Predictions.

Analysis

The key debate is earnings quality, not whether prediction-market activity is growing. If the product brings incremental users and cross-sells into sportsbook/iGaming, it could lower acquisition costs; if activity is mostly existing customers shifting wagers, reported volume may rise without comparable net-revenue growth. Sportsbook handle is a weak proxy for monetization because hold, promotions, and customer mix drive conversion to revenue. The cut to StoneX’s 2026 EBITDA estimate alongside higher product investment is a useful counterweight to the claim that estimates have bottomed: the market may be pricing a recovery before unit economics are demonstrated.

Near term (days to weeks), the upgrade and low expectations can support a relief rally, but analyst targets are not evidence of a forecast inflection. Over 1–3 months, watch quarterly net revenue and EBITDA against handle growth, promotional intensity, and incremental Predictions spending. Over 6–18 months, regulatory treatment and whether prediction markets expand the addressable market or cannibalize regulated sportsbook activity are the structural swing factors. Flutter/FanDuel and PENN could face similar competitive pressure if the channel scales, but may also respond with promotions that compress industry economics.

Contrarian angle: investors may be treating prediction markets as purely a threat; a compliant, lower-friction entry point could widen the funnel. Conversely, volume headlines may overstate value if economics are weak or regulation constrains distribution. No broad sector read-through is justified from one company’s product trajectory.

Key Decisions for Investors

• Consider a small, staged long in DKNG rather than chasing the analyst upgrade; add only if reported net-revenue conversion and EBITDA trends validate that product engagement is incremental. The supplied $18.52 52-week low is a near-term thesis check, not a guaranteed stop.
• Falsify the long thesis if DKNG breaks and sustains below the recent low, cuts forward EBITDA expectations again, or shows rising handle/activity without improving net revenue or margins.
• Track quarterly product-level economics, customer overlap/cannibalization, promotional spend, and regulatory developments for prediction markets; these are missing inputs needed to underwrite durable earnings contribution.
• Avoid treating competitor exposure as a direct pair trade yet: first verify whether prediction-market growth is drawing new customers or reallocating existing wagers, and whether rival promotions are worsening customer-acquisition economics.